These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22811583)

  • 1. HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy.
    Lin KT; Wang YW; Chen CT; Ho CM; Su WH; Jou YS
    Clin Cancer Res; 2012 Sep; 18(17):4691-701. PubMed ID: 22811583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
    Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
    Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors.
    Kim DR; Park MY; Lim HJ; Park JS; Cho YJ; Lee SW; Yoon HI; Lee JH; Kim YS; Lee CT
    Int J Mol Med; 2012 Feb; 29(2):218-24. PubMed ID: 22075951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.
    Hsieh YJ; Hwu L; Chen YC; Ke CC; Chen FD; Wang HE; Lin KP; Yeh HH; Chang CW; Liu RS
    J Nucl Med; 2014 Apr; 55(4):678-85. PubMed ID: 24639460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
    Yu C; Friday BB; Lai JP; McCollum A; Atadja P; Roberts LR; Adjei AA
    Clin Cancer Res; 2007 Feb; 13(4):1140-8. PubMed ID: 17317822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
    Botrugno OA; Santoro F; Minucci S
    Cancer Lett; 2009 Aug; 280(2):134-44. PubMed ID: 19345000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy.
    Ahmad M; Hamid A; Hussain A; Majeed R; Qurishi Y; Bhat JA; Najar RA; Qazi AK; Zargar MA; Singh SK; Saxena AK
    DNA Cell Biol; 2012 Oct; 31 Suppl 1():S62-71. PubMed ID: 22462686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
    Frew AJ; Johnstone RW; Bolden JE
    Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways.
    Matsuoka H; Tsubaki M; Yamazoe Y; Ogaki M; Satou T; Itoh T; Kusunoki T; Nishida S
    Exp Cell Res; 2009 Jul; 315(12):2022-32. PubMed ID: 19393235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor.
    Mataga MA; Rosenthal S; Heerboth S; Devalapalli A; Kokolus S; Evans LR; Longacre M; Housman G; Sarkar S
    Anticancer Res; 2012 Jul; 32(7):2523-9. PubMed ID: 22753709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
    Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP
    Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.
    Regel I; Merkl L; Friedrich T; Burgermeister E; Zimmermann W; Einwächter H; Herrmann K; Langer R; Röcken C; Hofheinz R; Schmid R; Ebert MP
    Gastroenterology; 2012 Jul; 143(1):99-109.e10. PubMed ID: 22465428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.
    Li J; Zhang T; Yang F; He Y; Dai F; Gao D; Chen Y; Liu M; Yi Z
    Br J Pharmacol; 2015 Aug; 172(15):3817-30. PubMed ID: 25884486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression analysis of Cdc42 in lung cancer and modulation of its expression by curcumin in lung cancer cell lines.
    Chen QY; Jiao DM; Yao QH; Yan J; Song J; Chen FY; Lu GH; Zhou JY
    Int J Oncol; 2012 May; 40(5):1561-8. PubMed ID: 22266952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases.
    Hölsken A; Eyüpoglu IY; Lueders M; Tränkle C; Dieckmann D; Buslei R; Hahnen E; Blümcke I; Siebzehnrübl FA
    Acta Neuropathol; 2006 Aug; 112(2):205-15. PubMed ID: 16773328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
    Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
    Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
    Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
    Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
    De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
    J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.